Floatz logo

Chiauranib

Relapsed or Refractory

Chipscreen Biosciences, Ltd.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Relapsed or Refractory cohort.

Asset / SponsorPhaseRating
Carfilzomib
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
cc-5013
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
DEXAMETHASONE
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC
Romidepsin
Memorial Sloan Kettering Cancer Center
Phase 1/2CCC

Same molecule, other indications

Chiauranib is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
ChiauranibDormant
B
Indicative ·
60 / 100
View asset →
PaclitaxelDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →